First Outcomes Trial Results For PCSK9 Drugs Will Come In 2016

In less than a year we may know a whole lot more about the PCSK9 inhibitors than we do now. Since the approval earlier this year of Repatha (evolocumab, Amgen) and Praluent (alirocumab, Regeneron and Sanofi) critics and benefit managers have recommended strict limitations on use of the drugs because of the absence of evidence showing clinical benefit....Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Prevention, Epidemiology & Outcomes People, Places & Events Policy & Ethics PCSK9 Repatha Praluent Fourier choelsterol outcomes trials Source Type: blogs